Stage‐specific impact of pelvic lymph node dissection on survival in patients with non‐metastatic bladder cancer treated with radical cystectomy
Study Type – Therapy (cohort) Level of Evidence 2b What's known on the subject? and What does the study add? In patients treated with radical cystectomy, pelvic lymph node dissection may have a beneficial effect on cancer control outcomes. We examined the effect of pelvic lymph node dissection...
Saved in:
Published in | BJU international Vol. 109; no. 8; pp. 1147 - 1154 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.04.2012
Wiley-Blackwell Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Study Type – Therapy (cohort)
Level of Evidence 2b
What's known on the subject? and What does the study add?
In patients treated with radical cystectomy, pelvic lymph node dissection may have a beneficial effect on cancer control outcomes.
We examined the effect of pelvic lymph node dissection on stage‐specific cancer control outcomes.
OBJECTIVE
•
To examine the effect of stage‐specific pelvic lymph node dissection (PLND) on cancer‐specific (CSM) and overall mortality (OM) rates at radical cystectomy (RC) for bladder cancer.
METHODS
•
Overall, 11 183 patients were treated with RC within the Surveillance, Epidemiology, and End Results database.
•
Univariable and multivariable Cox regression analyses tested the effect of PLND on CSM and OM rates, after stratifying according to pathological tumour stage.
RESULTS
•
Overall, PLND was omitted in 25% of patients, and in 50, 35, 27, 16 and 23% of patients with respectively pTa/is, pT1, pT2, pT3 and pT4 disease (P < 0.001).
•
For the same stages, the 10‐year CSM‐free rates for patients undergoing PLND compared with those with no PLND were, respectively, 80 vs 71.9% (P = 0.02), 81.7 vs 70.0% (P < 0.001), 71.5 vs 56.1% (P = 0.001), 43.7 vs 38.8% (P = 0.006), and 35.1 vs 32.0% (P = 0.1).
•
In multivariable analyses, PLND omission was associated with a higher CSM in patients with pTa/is, pT1 and pT2 disease (all P ≤ 0.01), but failed to achieve independent predictor status in patients with pT3 and pT4 disease (both P ≥ 0.05).
•
Omitting PLND predisposed to a higher OM across all tumour stages (all P ≤ 0.03).
CONCLUSIONS
•
Our results indicate that PLND was more frequently omitted in patients with organ‐confined disease.
•
The beneficial effect of PLND on cancer control outcomes was more evident in these patients than in those with pT3 or pT4 disease.
•
PLND at RC should always be considered, regardless of tumour stage. |
---|---|
Bibliography: | These two authors contributed equally to the study. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 content type line 23 |
ISSN: | 1464-4096 1464-410X 1464-410X |
DOI: | 10.1111/j.1464-410X.2011.10482.x |